Company intelligence / Profile preview

ImmunoViroTherapy Therapeutics

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

ImmunoViroTherapy Therapeutics is a clinical-stage biotechnology company focused on developing innovative oncolytic virus therapies for the treatment of cancer. The company utilizes a proprietary oncolytic Herpes Simplex Virus (oHSV) platform to create genetically modified viruses that selectively target and destroy cancer cells while inducing a robust immune response. Its lead program, IVT-8001, is a next-generation oHSV-1 candidate currently in Phase 2 clinical development for the treatment of glioblastoma multiforme. Headquartered in Suzhou, China, ImmunoViroTherapy Therapeutics is advancing a pipeline of viral immunotherapies designed to treat a variety of refractory solid tumors. The company's technology is based on pioneering research from the University of Tokyo.

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyGene therapy
Industry: Biotech

Beyond the preview

Go deeper on ImmunoViroTherapy Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunoViroTherapy Therapeutics.

Explore the full profile